logo
  

Myriad Genetics Reports Regulatory Approval Of BRACAnalysis In Japan

Myriad Genetics, Inc. (MYGN) announced the Japan's Ministry of Health, Labour and Welfare has approved the BRACAnalysis Diagnostic System for Hereditary Breast and Ovarian Cancer risk assessment in patients with breast cancer.

BRACAnalysis is a genetic test that identifies germline mutations in the BRCA1/2 genes. This test will assist physicians in determining which women with breast cancer have Hereditary Breast and Ovarian Cancer syndrome and qualify for additional medical management.

Myriad has an exclusive partnership with SRL Inc. to commercialize the BRACAnalysis Diagnostic System in Japan.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of BMW Group were losing around 5 percent in German trading after the luxury automaker warned Tuesday that its second half-year is likely to be more volatile, affected by supply bottlenecks, high prices for raw materials and a shortage of semiconductors. This was despite reporting strong second-quarter results driven by solid demand. Brooklyn, New York -based Golden Natural Products, Inc. is recalling two dried apricot products as they contain undeclared sulfites, the U.S. Food and Drug Administration said. The recall involves Dried Apricot Subkhon with Bone and Dried Apricot Subkhon Jumbo. Pfizer and Moderna have raised the prices of their respective Covid vaccines for European Union, the Financial Times reported. Pharmaceutical giants renegotiated their covid vaccine supply contract with the EU citing global inflation, supply chain bottleneck and a high demand for the vaccines. A similar price hike is expected in other markets.
Follow RTT